Tumor-infiltrating lymphocytes as a prognostic biomarker in patients with ductal carcinoma in situ of the breast: Correspondence.

IF 3 3区医学 Q2 ONCOLOGY

Breast Cancer Research and Treatment Pub Date : 2024-12-01 Epub Date: 2024-09-24 DOI:10.1007/s10549-024-07489-2

Hinpetch Daungsupawong, Viroj Wiwanitkit

引用次数: 0

查看原文本刊更多论文

作为乳腺导管原位癌患者预后生物标志物的肿瘤浸润淋巴细胞：通讯。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Breast Cancer Research and Treatment 医学-肿瘤学

CiteScore

6.80

自引率

2.60%

发文量

342

审稿时长

1 months

期刊介绍： Breast Cancer Research and Treatment provides the surgeon, radiotherapist, medical oncologist, endocrinologist, epidemiologist, immunologist or cell biologist investigating problems in breast cancer a single forum for communication. The journal creates a "market place" for breast cancer topics which cuts across all the usual lines of disciplines, providing a site for presenting pertinent investigations, and for discussing critical questions relevant to the entire field. It seeks to develop a new focus and new perspectives for all those concerned with breast cancer.